Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml

Journal of Urology

Volumn 189, Issue 1, 2013, Pages 111-115

  Meeks, Joshua J ^a   Maschino, Alexandra C ^a   McVary, Kevin T ^b   Sandhu, Jaspreet S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

laser therapy; prostate; prostate specific antigen; prostatic neoplasms; transurethral resection of prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL RESECTION; UNITED STATES;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 84870956270     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.08.093     Document Type: Article

References (16)

1. J.T. Wei, E. Calhoun, S.J. Jacobsen Urologic Diseases in America project: benign prostatic hyperplasia J Urol 179 2008 S75
2. X. Yu, S.P. Elliott, T.J. Wilt Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies J Urol 180 2008 241
3. T. Bach, R. Muschter, R. Sroka Laser treatment of benign prostatic obstruction: basics and physical differences Eur Urol 61 2012 317
4. K. Horasanli, M.S. Silay, B. Altay Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial Urology 71 2008 247
5. R.M. Hoffman, R. MacDonald, T.J. Wilt Laser prostatectomy for benign prostatic obstruction Cochrane Database Syst Rev 2004 CD001987
6. J. Rassweiler, D. Teber, R. Kuntz Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention Eur Urol 50 2006 969
7. D.E. Chung, J.S. Wysock, R.K. Lee Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia J Urol 186 2011 977
8. C. Capitán, C. Blázquez, M.D. Martin GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up Eur Urol 60 2011 734
9. A. Al-Ansari, N. Younes, V.P. Sampige GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up Eur Urol 58 2010 349
10. B.T. Helfand, A.K. Mongiu, D. Kan Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease BJU Int 104 2009 304
11. U. Capitanio Contemporary management of patients with T1a and T1b prostate cancer Curr Opin Urol 21 2011 252
12. J.J. Meeks, G.M. Habermacher, B. Le Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP Urology 72 2008 948 e11
13. R. Rajab, G. Fisher, M.W. Kattan An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent Mod Pathol 24 2011 58
14. A. Ouzzane, P. Puech, L. Lemaitre Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading Urology 78 2011 1356
15. B.T. Helfand, A.M. Manvar, G.B. Auffenberg Holmium laser ablation and enucleation of the prostate: a pilot study of the hybrid technique Can J Urol 17 2010 5190
16. B.T. Helfand, C.B. Anderson, A. Fought Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia Urology 74 2009 177